Hematologic Disorders Archives - Page 3 of 81 - MPR

Hematologic Disorders

First Rituximab Biosimilar Truxima Gets FDA Approval

The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.

Lanadelumab Examined for Attack Rate in Hereditary Angioedema

During the treatment period, the mean number of attacks per month was 1.97 for placebo and 0.48, 0.53, and 0.26 for the lanadelumab groups, respectively. The mean differences in the attack rate per month compared with placebo were −1.49, −1.44, and −1.71, respectively.